CNS/Neurology: AndzonBio2

About this session

AndzonBio2 is a VC-backed preclinical biotechnology company developing first-in-class small molecule therapies targeting neuroinflammation for neurological disorders.Founded 2025 with a 3 M€ in seed funding from AdBio Partners and Inserm Transfert, the company is led by an international team with significant entrepreneurial / BD / scientific / drug development experience in neuroscience. We develop therapeutics modulating neuroinflammatory pathways which are increasingly recognized as a pathological driver in multiple brain disorders.

Speaker

• SL

  Simon Loiodice

  COO · AndzonBio2

  Speaker